Palliation of advanced esophageal carcinoma by photodynamic therapy and irradiation

Maier, Andrea B.; Tomaselli, Florian; Gebhard, Florian; Rehak, Peter; Smolle, Josef; Smolle‐Jüttner, Freyja Maria

doi:10.1016/s0003-4975(99)01440-x

Cited by 59 publications

(64 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These objectives are achieved in the majority of PDT-treated cases. [77][78][79][80] PDT is also used in patients with early mucosal tumors unsuitable for surgery. Long-term survival of 5 or more years is achieved in 50 to 60%.…”

Section: 75mentioning

confidence: 99%

Untitled

2015

Surg J

View full text Add to dashboard Cite

Section: 75mentioning

confidence: 99%

Untitled

2015

Surg J

View full text Add to dashboard Cite

“…[107][108][109][110][111][112][113][114][115][116][117][118][119] Three studies were available only as abstracts, 107,110,111 the rest were published as full papers. In a small number of trials, the presented data did not appear to entirely support the authors' conclusions; this has been indicated in the data extraction tables.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…110 Eight studies reported on palliative PDT treatments for oesophageal cancer, four RCTs 112-114,119 and four non-randomised comparative trials. [115][116][117][118] Participants in six studies were diagnosed with advanced oesophageal cancer, and overall most trials included only patients who were not eligible for resection due to anatomical restrictions, poor health or refusal. Comparators in these trials included chemotherapy, radiotherapy, neodymium-doped yttrium aluminium garnet (Nd:YAG) laser or PDT.…”

Section: Study Characteristicsmentioning

confidence: 99%

A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett’s oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin

Fayter

Corbett²,

Heirs³

et al. 2010

Health Technol Assess

126

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of project...

show abstract

“…Furthermore, light fluence rate and the fluence (also referred to as light dose) delivered to the tissue were demonstrated to strongly influence the severity of PDT-induced tissue damage [5]. In previous oesophageal PDT studies [1,[6][7][8][9][10][11], light dosimetry was defined as either an estimation of the primary fluence rate (based on the total output power of a cylindrical diffuser divided by the area to be treated) or merely the light output power per length of diffuser. This approach assumes a radially emitting cylindrical diffuser and does not account for tissue light backscattering and reflection.…”

Section: Introductionmentioning

confidence: 99%

In situ light dosimetry during photodynamic therapy of Barrett's esophagus with 5‐aminolevulinic acid

et al. 2002

View full text Add to dashboard Cite

Background and Objectives: Previous studies with PhotoDynamic Therapy (PDT) in bladder and bronchi have shown that due to scattering and reflection, the actually delivered fluence rate on the surface in a hollow organ can be significantly higher than expected. In this pilot study, we investigated the differences between the primary calculated and the actual measured fluence rate during PDT of Barrett's Esophagus (BE) using 23 independent clinical measurements in 15 patients. Study Design/Materials and Methods: A KTP-dye module laser at 630 nm was used as light source. Light delivery was performed using a cylindrical light diffuser inserted in the center of an inflatable transparent balloon with a length corresponding to the length of the Barrett's epithelium. The total light output power of the cylindrical diffuser was calibrated using an integrating sphere to deliver a primary fluence rate of 100 mW cm À2 . Two fiber-optic pseudo sphere isotropic detectors were placed on the balloon and were used to measure fluence rate at the surface of the esophageal wall during PDT. Results and Conclusions: The actual fluence rate measured was 1.5-3.9 times higher than the primary fluence rate for 630 nm. In general, the fluence rate amplification factor decreased with increasing redness of the tissue and was less for shorter diffusers. Fluence rate variations in time were observed which coincided with patients coughing, movement, and esophageal spasms. These factors combined with inter patient variability of the fluence rate measured appears to justify the routine application of this technique in PDT of BE.

show abstract

Palliation of advanced esophageal carcinoma by photodynamic therapy and irradiation

Cited by 59 publications

References 15 publications

Untitled

Untitled

A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett’s oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin

In situ light dosimetry during photodynamic therapy of Barrett's esophagus with 5‐aminolevulinic acid

Contact Info

Product

Resources

About